Chinook Therapeutics, Inc. (KDNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
KDNY POWR Grades
- Sentiment is the dimension where KDNY ranks best; there it ranks ahead of 97.56% of US stocks.
- KDNY's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- KDNY ranks lowest in Momentum; there it ranks in the 12th percentile.
KDNY Stock Summary
- Of note is the ratio of Chinook Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.53% of US stocks have a lower such ratio.
- With a price/sales ratio of 17.35, Chinook Therapeutics Inc has a higher such ratio than 91.79% of stocks in our set.
- Revenue growth over the past 12 months for Chinook Therapeutics Inc comes in at 6,142.44%, a number that bests 99.69% of the US stocks we're tracking.
- Stocks that are quantitatively similar to KDNY, based on their financial statements, market capitalization, and price volatility, are RPTX, SNDX, LYRA, TGTX, and OVID.
- To dig deeper into the stock's financial statements, go to KDNY's page on browse-edgar?action=getcompany&CIK=0001435049.
KDNY Valuation Summary
- In comparison to the median Healthcare stock, KDNY's price/earnings ratio is 112.05% lower, now standing at -4.4.
- Over the past 78 months, KDNY's EV/EBIT ratio has gone up 157.4.
- KDNY's EV/EBIT ratio has moved up 157.4 over the prior 78 months.
Below are key valuation metrics over time for KDNY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KDNY | 2021-08-31 | -33.2 | 2.0 | -4.4 | -3.8 |
| KDNY | 2021-08-30 | -33.0 | 2.0 | -4.4 | -3.8 |
| KDNY | 2021-08-27 | -34.0 | 2.1 | -4.5 | -3.9 |
| KDNY | 2021-08-26 | -34.0 | 2.1 | -4.5 | -3.9 |
| KDNY | 2021-08-25 | -33.1 | 2.0 | -4.4 | -3.8 |
| KDNY | 2021-08-24 | -33.4 | 2.1 | -4.5 | -3.8 |
KDNY Growth Metrics
- Its 3 year cash and equivalents growth rate is now at -5.45%.
- The year over year revenue growth rate now stands at -146.84%.
- Its 4 year revenue growth rate is now at -59.56%.
The table below shows KDNY's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 51.625 | -102.744 | -102.937 |
| 2021-09-30 | -22.095 | -93.82 | -153.374 |
| 2021-06-30 | -18.312 | -82.537 | -137.218 |
| 2021-03-31 | -12.772 | -76.064 | -111.262 |
| 2020-12-31 | 0.827 | -55.848 | -81.622 |
| 2020-09-30 | 26.944 | -64.34 | -58.145 |
KDNY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KDNY has a Quality Grade of C, ranking ahead of 33.61% of graded US stocks.
- KDNY's asset turnover comes in at -0.049 -- ranking 679th of 681 Pharmaceutical Products stocks.
- YMTX, VTRS, and CRIS are the stocks whose asset turnover ratios are most correlated with KDNY.
The table below shows KDNY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | -0.049 | 1 | -0.700 |
| 2021-03-31 | -0.038 | 1 | -0.610 |
| 2020-12-31 | 0.003 | 1 | -0.489 |
| 2020-09-30 | 0.099 | 1 | -0.381 |
| 2020-06-30 | 0.097 | 1 | -0.389 |
| 2020-03-31 | 0.089 | 1 | -0.375 |
KDNY Price Target
For more insight on analysts targets of KDNY, see our KDNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.25 (Strong Buy) |
KDNY Stock Price Chart Interactive Chart >
KDNY Price/Volume Stats
| Current price | $15.42 | 52-week high | $19.85 |
| Prev. close | $13.88 | 52-week low | $10.48 |
| Day low | $13.84 | Volume | 845,300 |
| Day high | $15.48 | Avg. volume | 434,561 |
| 50-day MA | $14.97 | Dividend yield | N/A |
| 200-day MA | $13.93 | Market Cap | 850.83M |
Chinook Therapeutics, Inc. (KDNY) Company Bio
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Latest KDNY News From Around the Web
Below are the latest news stories about Chinook Therapeutics Inc that investors may wish to consider to help them evaluate KDNY as an investment opportunity.
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development SummitSEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022. Chinook will participate in the following panel and presentations: Panel Discussion: Challenges & Opportunities in Drug Development for Ra |
Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the ISN World Congress of Nephrology 2022 from February 24 – 27, 2022. The following abstracts will be presented as poster presentations at the ISN World Congress of Nephrology 2022: Atrasentan Abstract WCN22-0484 A Phase 3, Randomized, Dou |
Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceSEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:00 am ET. To access the live webcast and subsequent archived recording of this and other |
Chinook Therapeutics, Inc. (NASDAQ:KDNY) insider upped their holding by 10% earlier this yearFrom what we can see, insiders were net buyers in Chinook Therapeutics, Inc.'s ( NASDAQ:KDNY ) during the past 12... |
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SEATTLE, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 150,000 shares of common stock with a grant date of January 31, 2022 (the “Inducement Grant”) to one new employee. The stock o |
KDNY Price Returns
| 1-mo | 3.14% |
| 3-mo | 18.80% |
| 6-mo | -1.22% |
| 1-year | -6.55% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -5.46% |
| 2021 | 2.84% |
| 2020 | 168.81% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...